Long-term outcome in a patient with pulmonary hypertension and hereditary hemorrhagic telangiectasia

Chest

Volumn 131, Issue 4, 2007, Pages 984-987

  Minai, Omar A ^a   Rigelsky, Christina ^a   Eng, Charis ^a   Arroliga, Alejandro C ^b   Stoller, James K ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Genetic; Hereditary hemorrhagic telangiectasia; Pulmonary hypertension; Pulmonary vascular disease; Shunt

Indexed keywords

BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; NIFEDIPINE; PROSTACYCLIN; UNIPROST; WARFARIN;

ADULT; ARTERIOVENOUS MALFORMATION; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; EPISTAXIS; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; LUNG ANGIOGRAPHY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE;

EID: 34247198542     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2275     Document Type: Article

References (10)

1. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:325-334
2. Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary hemorrhagic telangiectasia. J Med Genet 2003; 40:865-871
3. Shovlin CL, Guttmacher AE, Buscarini, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66-67
4. Waite KA, Eng C. From developmental disorder to cancer: it's all in the BMP/TGFB family. Nature Rev Genet 2003; 4:763-773
5. Lesca G, Burnichon N, Raux G, et al. On behalf of the French Rendu-Osler Network: distribution of ENG and ACVRL1 (ALK1) mutations in French HHT-patients [abstract]. Hum Mutat 2006; 27:598
6. Bossler AD, Richards J, George C, et al. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006; 27:667-675
7. Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 2006; 140:2155-2162
8. Harradine KA, Akhurst RJ. Mutations of TGFβ signaling ? molecules in human disease. Ann Med 2006; 38:403-414
9. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3:1011-1022
10. Schlag K, Opitz C, Wensel R, et al. Pulmonale hypertonie bei hereditarer hamorrhaischer telangiektasie (Morbus Osler): Verlauf uber 10 Jahre. Dtsch Med Wochenschr 2005; 130: 1434-1437